Eli Lilly and Company LLY

1,183.46 1.57 0.13% as of 25 Sep
Market cap
$1.11T
P/E
39.7×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Eli Lilly and Company (LLY) P/S ratio

As of 25 September 2026, Eli Lilly and Company (LLY) trades at a P/S ratio of 13.3×. Over the past ten years it has ranged from 3.3× (December 2016) to 22.8× (June 2024); the current reading is higher than 77% of that period. That is above the Drug Manufacturers General industry median of 3.3× and above the Healthcare sector median of 3.8×.

P/S ratio, daily

Annual

Period P/S ratio Change
FY2025 14.8× (4.15%)
FY2024 15.4× (1.20%)
FY2023 15.6× 35.48%
FY2022 11.5× 30.35%
FY2021 8.8× 41.66%
FY2020 6.2× 13.90%
FY2019 5.5× (0.92%)
FY2018 5.5× 24.06%
FY2017 4.5× 19.89%
FY2016 3.7× (17.02%)

Quarterly

Period P/S ratio Change
Jun 2026 13.4× 17.99%
Mar 2026 11.4× (23.03%)
Dec 2025 14.8× 28.46%
Sep 2025 11.5× (12.37%)
42 more quarters

Against its own ten years

Low 3.3× High 22.8×
Ten-year median 6.3×
Current reading's percentile 77

P/S ratio against peers

Company P/S ratio
PFE Pfizer Inc. compare 2.6×
AZN AstraZeneca PLC compare 4.2×
NVS Novartis AG compare 4.9×
MRK Merck & Co., Inc. compare 5.5×
AMGN Amgen Inc. compare 5.9×
GILD Gilead Sciences, Inc. compare 6.2×
JNJ Johnson & Johnson compare 6.7×
ABBV AbbVie Inc. compare 7.3×
LLY Eli Lilly and Company 13.3×
Drug Manufacturers General industry median 3.3×
Healthcare sector median 3.8×
Market median 2.0×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on LLY